Inactive Instrument

Analyst Reco. Ambrx Biopharma Inc.

Equities

JMP Securities Downgrades Ambrx Biopharma to Market Perform From Market Outperform	10/01	MT
B. Riley Downgrades Ambrx Biopharma to Neutral From Buy on Heels of Announced Sale to Johnson & Johnson, Adjusts PT to $28 From $26	09/01	MT
BTIG Downgrades Ambrx Biopharma to Neutral From Buy	08/01	MT
Goldman Sachs Trims Ambrx Biopharma's Price Target to $9 From $10, Keeps Neutral Rating	15/11	MT
RBC Trims Price Target on Ambrx Biopharma to $32 From $33, Keeps Outperform, Speculative Risk	14/11	MT
RBC Lifts Price Target on Ambrx Biopharma to $33 From $29, Keeps Outperform Rating, Speculative Risk Qualifier	23/23/23	MT

No results for this search